GlobeNewswire

Veld Pharmaceuticals GmbH Announces Collaboration with Chiesi Farmaceutici S.p.A to Expand Access to Rare Disease Therapies Across Africa
13/04/2026
Managed Access Program to support physician-led access to nine rare-disease therapies in accordance with local regulatory frameworks ZUG, Switzerland, April 13, 2026 (GLOBE NEWSWIRE) -- Veld Pharmaceuticals GmbH (“Veld [...]
With Brain Scan Volume Momentum Accelerating, Firefly Makes History by Building the World’s First Known 200,000+ Standardized EEG/ERP Depository
13/04/2026
- Firefly’s total brain scan volumes have increased sequentially by higher percentages in each of the past four quarters - - Firefly is harnessing increased data and NVIDIA L40S GPU acceleration to power next-generation [...]
NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
13/04/2026
VANCOUVER, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative [...]
Glass House Brands Announces California Retail Joint Venture with Vireo Growth
13/04/2026
LONG BEACH, Calif. and TORONTO, April 13, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House") (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX: GHBWF) and Vireo Growth Inc. ("Vireo") (CSE: [...]
Vireo Growth Announces California Retail Joint Venture with Glass House Brands
13/04/2026
MINNEAPOLIS and LONG BEACH, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (“Vireo”) (CSE: VREO; OTCQX: VREOF) and Glass House Brands Inc. (“Glass House”) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: [...]
Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors
13/04/2026
Physician and seasoned life sciences investor with more than two decades of experience across clinical practice, biotechnology investing, and board leadership Author of a visionary 2015 Journal of Investigative [...]
Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement
13/04/2026
Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement Peer-reviewed consensus redefines debridement from simple tissue removal to a more comprehensive biologically active [...]
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
13/04/2026
41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30% MRD Reduction Occurred Rapidly Following Cema-Cel Treatment with a 97.7% [...]
Gelatide Drops Investigated (2026 Report) What Consumers Should Verify Before Buying
13/04/2026
A 2026 consumer-focused evaluation of Gelatide that analyses its marketing claims, ingredient profile, pricing structure, and key factors consumers should verify before making a purchase. Los Angeles, April 13, 2026 ( [...]
Leanzene Gummies Examined: 2026 Consumer-Focused Breakdown of Ingredients, Claims & Label Transparency
13/04/2026
NEW YORK, April 13, 2026 (GLOBE NEWSWIRE) -- As interest in metabolic support supplements grows, products like Leanzene Gummies are drawing attention among consumers exploring apple cider vinegar and BHB-based formulas [...]
Novo Nordisk A/S - share repurchase programme
13/04/2026
Bagsværd, Denmark, 13 April 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
Regeneron and Telix Announce Strategic Radiopharma Collaboration
13/04/2026
Regeneron and Telix to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model Collaboration combines Regeneron’s leading antibody discovery/development [...]
Telix and Regeneron Announce Strategic Radiopharma Collaboration
13/04/2026
Telix and Regeneron to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model. Collaboration combines Telix’s expertise in radiopharmaceutical development [...]
ProSomnus® Receives FDA Class II Clearance for RPMO2 OSA Device
13/04/2026
SAN FRANCISCO, April 13, 2026 (GLOBE NEWSWIRE) -- ProSomnus Sleep Technologies (“the Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy® and pioneer in Smart Sleep Medicine™, today announced that the [...]
Major Shareholder Announcement
13/04/2026
April 13, 2026 Company Announcement No. 8 Major Shareholder Announcement COPENHAGEN, DENMARK and BOSTON, MA, USA, 13 April 2026 – BioPorto A/S (“BioPorto” or the “Company”) (CPH: BIOPOR) hereby announces, pursuant to [...]
Smart Minimalism, Supreme Efficiency: CUKTECH 15 Charging Station Makes Its Debut in Malaysia
13/04/2026
KUALA LUMPUR, Malaysia, April 13, 2026 (GLOBE NEWSWIRE) -- CUKTECH, a global leader in intelligent power solutions, today announced the official Malaysian launch of its highly anticipated flagship: the CUKTECH 15 [...]
Epitopea Strengthens Scientific Advisory Board with Appointment of Leading Authority in Cancer, Lisa Butterfield
13/04/2026
CAMBRIDGE, United Kingdom and MONTREAL, April 13, 2026 (GLOBE NEWSWIRE) -- Epitopea , a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies for hard-to-treat [...]
Epitopea renforce son comité consultatif scientifique avec la nomination de Lisa Butterfield, figure de renom dans le domaine du cancer
13/04/2026
CAMBRIDGE, Royaume-Uni et MONTRÉAL, 13 avr. 2026 (GLOBE NEWSWIRE) -- Epitopea , une société transatlantique spécialisée dans l'immunothérapie contre le cancer qui développe des immunothérapies à base d'ARN accessibles [...]
Boehringer Ingelheim introduces LENZELTA®: A new vaccine advancing mastitis prevention in dairy cows
13/04/2026
LENZELTA ® is a new vaccine significantly reducing the incidence and severity of clinical mastitis in vaccinated cows and heifers 1 . Administration is simple with two doses during the dry-off period. Mastitis continues [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum